PCVX

Vaxcyte
PCVX

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$4.46B
EV
$2.87B
Shares Outstanding
129.00M
Beta
1.20

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$125.75
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Vaxcyte, Inc.

gainify
PCVX

Vaxcyte, Inc.

PCVX

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of inv...

Sector

Healthcare

Industry

Biotechnology

CEO

Pickering, Grant

Employees

414

IPO Date

2020-06-12

Headquarters

825 Industrial Road, Suite 300, San Carlos, California, 94070, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.